Skip to main content
SpringerLink
Log in

Botulinum Toxin Treatment in Parkinson’s Disease and Atypical Parkinsonian Disorders

  • Chapter
  • First Online:
Botulinum Toxin Treatment in Clinical Medicine

  • 1112 Accesses

Abstract

Botulinum toxin (BoNT) is an effective therapy for multiple neurological conditions. Parkinson’s disease and atypical parkinsonism are neurodegenerative conditions in which BoNT has emerged as a therapeutic option for many symptoms, especially when other medical therapies have failed to provide satisfactory relief. BoNT is helpful in the management of blepharospasm, bruxism, camptocormia, cervical dystonia including anterocollis, sialorrhea, seborrhea, and overactive bladder. BoNT is a safe and effective therapy for this patient population when administered by skilled physicians.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Dressler D. Botulinum toxin drugs: brief history and outlook. J Neural Transm (Vienna). 2016;123(3):277–9.

    Article  CAS  Google Scholar 

  2. Jankovic J. Botulinum toxin. In: Kompoliti K, Verhagen Metman L, editors. Encyclopedia of movement disorders, vol. 1. Oxford: Academic Press; 2010a. p. 144–50.

    Chapter  Google Scholar 

  3. Jankovic J. Botulinum toxin: State of the art. Mov Disord. 2017. doi:10.1002/mds.27072. In press.

    Google Scholar 

  4. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368–76.

    Article  CAS  PubMed  Google Scholar 

  5. Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol. 2014;71:499–504.

    Article  PubMed  Google Scholar 

  6. Stamelou M, Bhatia KP. Atypical parkinsonism: diagnosis and Treatment. Neurol Clin. 2015;33:39–56.

    Article  PubMed  Google Scholar 

  7. Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon. 2009;54:614–23.

    Article  CAS  PubMed  Google Scholar 

  8. Lotia M, Jankovic J. New and emerging medical therapies in Parkinson’s disease. Expert Opin Pharmacother. 2016a;17(7):895–909.

    Article  CAS  PubMed  Google Scholar 

  9. Naumann M, Dressler D, Hallett M, Jankovic J, Schiavo G, Segal KR, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon. 2013;67:141–52.

    Article  CAS  PubMed  Google Scholar 

  10. Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the guideline development Subcommittee of the American Academy of Neurology. Neurology. 2016;86:1818–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94–114.

    Article  CAS  PubMed  Google Scholar 

  12. Bruno VA, Fox SH, Mancini D, Miyasaki JM. Botulinum toxin use in refractory pain and other symptoms in parkinsonism. Can J Neurol Sci. 2016;43(5):697–702.

    Article  PubMed  Google Scholar 

  13. Jankovic J. How do I examine for re-emergent tremor? Mov Disord Clin Pract. 2016;3:216–7.

    Article  Google Scholar 

  14. Lotia M, Jankovic J. Botulinum toxin for the treatment of tremor and tics. Semin Neurol. 2016b;36:54–63.

    Article  PubMed  Google Scholar 

  15. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001;56:1523–8.

    Article  CAS  PubMed  Google Scholar 

  16. Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996;11:250–6.

    Article  CAS  PubMed  Google Scholar 

  17. Jankovic J, Schwartz K. Botulinum toxin treatment of tremors. Neurology. 1991;41:1185–8.

    Article  CAS  PubMed  Google Scholar 

  18. Trosch RM, Pullman SL. Botulinum toxin A injections for the treatment of hand tremors. Mov Disord. 1994;9:601–9.

    Article  CAS  PubMed  Google Scholar 

  19. Pullman SL, Greene P, Fahn S, Pedersen SF. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol. 1996;53:617–24.

    Article  CAS  PubMed  Google Scholar 

  20. Henderson JM, Ghika JA, Van Melle G, Haller E, Einstein R. Botulinum toxin A in non-dystonic tremors. Eur Neurol. 1996;36:29–35.

    Article  CAS  PubMed  Google Scholar 

  21. Rahimi F, Bee C, Debicki D, Roberts AC, Bapat P, Jog M. Effectiveness of BoNT A in Parkinson’s disease upper limb tremor management. Can J Neurol Sci. 2013;40:663–9.

    Article  PubMed  Google Scholar 

  22. Rahimi F, Samotus O, Lee J, Jog M. Effective management of upper limb parkinsonian tremor by incobotulinumtoxinA injections using sensor-based biomechanical patterns. Tremor Other Hyperkin Mov. 2015b;5:348.

    Google Scholar 

  23. Mills R, Bahroo L, Pagan F. An update on the use of botulinum toxin therapy in Parkinson’s disease. Curr Neurol Neurosci Rep. 2015;15:511.

    Article  PubMed  CAS  Google Scholar 

  24. Rahimi F, Debicki D, Roberts-South A, Bee C, Bapat P, Jog M. Dynamic decomposition of motion in essential and parkinsonian tremor. Can J Neurol Sci. 2015a;42:116–24.

    Article  PubMed  Google Scholar 

  25. Erer S, Jankovic J. Hereditary chin tremor in Parkinson’s disease. Clin Neurol Neurosurg. 2007;109:784–5.

    Article  PubMed  Google Scholar 

  26. Hunker CJ, Abbs JH. Uniform frequency of parkinsonian resting tremor in the lips, jaw, tongue, and index finger. Mov Disord. 1990;5:71–7.

    Article  CAS  PubMed  Google Scholar 

  27. Schneider SA, Edwards MJ, Cordivari C, Macleod WN, Bhatia KP. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson’s disease. Mov Disord. 2006;21:1722–4.

    Article  PubMed  Google Scholar 

  28. Tarsy D, Ro SI. Unusual position-sensitive jaw tremor responsive to botulinum toxin. Mov Disord. 2006;21:277–8.

    Article  PubMed  Google Scholar 

  29. Jankovic J. Gait disorders. Neurol Clin. 2015;33(1):249–68.

    Article  PubMed  Google Scholar 

  30. Macht M, Kaussner Y, Moller JC, Stiasny-Kolster K, Eggert KM, Kruger HP, et al. Predictors of freezing in Parkinson’s disease: a survey of 6,620 patients. Mov Disord. 2007;22:953–6.

    Article  PubMed  Google Scholar 

  31. Giladi N, McDermott MP, Fahn S, Przedborski S, Jankovic J, Stern M, et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology. 2001b;56:1712–21.

    Article  CAS  PubMed  Google Scholar 

  32. Kuo SH, Kenney C, Jankovic J. Bilateral pedunculopontine nuclei strokes presenting as freezing of gait. Mov Disord. 2008;23:616–9.

    Article  PubMed  Google Scholar 

  33. Ashoori A, Eagleman DM, Jankovic J. Effects of auditory rhythm and music on gait disturbances in Parkinson’s disease. Front Neurol. 2015;6:234.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Nonnekes J, Snijders AH, Nutt JG, Deuschl G, Giladi N, Bloem BR. Freezing of gait: a practical approach to management. Lancet Neurol. 2015;14:768–78.

    Article  PubMed  Google Scholar 

  35. Espay AJ, Dwivedi AK, Payne M, Gaines L, Vaughan JE, Maddux BN, et al. Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. Neurology. 2011a;76:1256–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Fukada K, Endo T, Yokoe M, Hamasaki T, Hazama T, Sakoda S. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson’s disease. Med Hypotheses. 2013;80:209–12.

    Article  CAS  PubMed  Google Scholar 

  37. Malkani R, Zadikoff C, Melen O, Videnovic A, Borushko E, Simuni T. Amantadine for freezing of gait in patients with Parkinson disease. Clin Neuropharmacol. 2012;35:266–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petyt G, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson’s disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol. 2012;11:589–96.

    Article  CAS  PubMed  Google Scholar 

  39. Vercruysse S, Vandenberghe W, Munks L, Nuttin B, Devos H, Nieuwboer A. Effects of deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson’s disease: a prospective controlled study. J Neurol Neurosurg Psychiatry. 2014;85:871–7.

    Article  CAS  PubMed  Google Scholar 

  40. Giladi N, Gurevich T, Shabtai H, Paleacu D, Simon ES. The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study. J Neurol. 2001a;248:572–6.

    Article  CAS  PubMed  Google Scholar 

  41. Giladi N, Honigman S. Botulinum toxin injections to one leg alleviate freezing of gait in a patient with Parkinson’s disease. Mov Disord. 1997;12:1085–6.

    Article  CAS  PubMed  Google Scholar 

  42. Fernandez HH, Lannon MC, Trieschmann ME, Friedman JH. Botulinum toxin type B for gait freezing in Parkinson’s disease. Med Sci Monit. 2004;10:CR282–4.

    PubMed  Google Scholar 

  43. Gurevich T, Peretz C, Moore O, Weizmann N, Giladi N. The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson’s disease: a double blind placebo-controlled pilot study. Mov Disord. 2007;22:880–3.

    Article  PubMed  Google Scholar 

  44. Wieler M, Camicioli R, Jones CA, Martin WR. Botulinum toxin injections do not improve freezing of gait in Parkinson disease. Neurology. 2005;65:626–8.

    Article  CAS  PubMed  Google Scholar 

  45. Zhang LL, Canning SD, Wang XP. Freezing of gait in parkinsonism and its potential drug treatment. Curr Neuropharmacol. 2016;14:302–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863–73.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Jankovic J, Tintner R. Dystonia and parkinsonism. Parkinsonism Relat Disord. 2001;8:109–21.

    Article  CAS  PubMed  Google Scholar 

  48. Ashour R, Tintner R, Jankovic J. Striatal deformities of the hand and foot in Parkinson’s disease. Lancet Neurol. 2005;4:423–31.

    Article  PubMed  Google Scholar 

  49. Doherty KM, van de Warrenburg BP, Peralta MC, Silveira-Moriyama L, Azulay JP, Gershanik OS, et al. Postural deformities in Parkinson’s disease. Lancet Neurol. 2011;10(6):538–49.

    Article  PubMed  Google Scholar 

  50. Giladi N, Meer J, Honigman S. The use of botulinum toxin to treat “striatal” toes. J Neurol Neurosurg Psychiatry. 1994;57(5):659.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004;75(7):951–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Azher SN, Jankovic J. Clinical aspects of progressive supranuclear palsy. Handb Clin Neurol. 2008;89:461–73.

    Article  PubMed  Google Scholar 

  53. Clark D, Eggenberger E. Neuro-ophthalmology of movement disorders. Curr Opin Ophthalmol. 2012 Nov;23(6):491–6.

    Google Scholar 

  54. Esposito M, Fasano A, Crisci C, Dubbioso R, Iodice R, Santoro L. The combined treatment with orbital and pretarsal botulinum toxin injections in the management of poorly responsive blepharospasm. Neurol Sci. 2014;35:397–400.

    Article  PubMed  Google Scholar 

  55. Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm. 2008;115:585–91.

    Article  CAS  PubMed  Google Scholar 

  56. Cakmur R, Ozturk V, Uzunel F, Donmez B, Idiman F. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol. 2002;249:64–8.

    Article  CAS  PubMed  Google Scholar 

  57. Inoue K, Rogers JD. Botulinum toxin injection into Riolan’s muscle: somatosensory ‘trick’. Eur Neurol. 2007;58:138–41.

    Article  CAS  PubMed  Google Scholar 

  58. Hirota N, Hirota M, Mezaki T. Dystonic frowning without blepharospasm. Parkinsonism Relat Disord. 2008;14:579–80.

    Article  PubMed  Google Scholar 

  59. Romano S, Colosimo C. Procerus sign in progressive supranuclear palsy. Neurology. 2001;57:1928.

    Article  CAS  PubMed  Google Scholar 

  60. Fezza J, Burns J, Woodward J, Truong D, Hedges T, Verma A. A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm. J Neurol Sci. 2016;367:56–62.

    Article  CAS  PubMed  Google Scholar 

  61. Biuk D, Karin AA, Matić S, Barać J, Benasić T, Stiglmayer N. Quality of life in patients with blepharospasm. Coll Antropol. 2013;37(1):29–33.

    PubMed  Google Scholar 

  62. Martinez-Ramirez D, Giugni JC, Hastings E, et al. Comparable botulinum toxin outcomes between primary and secondary blepharospasm: a retrospective analysis. Tremor Other Hyperkinet Mov (N Y). 2014;4:286.

    Google Scholar 

  63. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefe’s Arch Clin Exp Ophthalmol. 1997;235:197–9.

    Article  CAS  Google Scholar 

  64. Sampaio C, Ferreira JJ, Simoes F, Rosas MJ, Magalhaes M, Correia AP, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1. Mov Disord. 1997;12:1013–8.

    Article  CAS  PubMed  Google Scholar 

  65. Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S, Team NTBS. Efficacy and safety of a new Botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303–12.

    Article  CAS  PubMed  Google Scholar 

  66. Quagliato EM, Carelli EF, Viana MA. Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment. Clin Neuropharmacol. 2010;33:27–31.

    CAS  PubMed  Google Scholar 

  67. Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol. 2009;23:137–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Karp BI, Alter K. Botulinum toxin treatment of blepharospasm, orofacial/oromandibular dystonia, and hemifacial spasm. Semin Neurol. 2016;36(1):84–91.

    Article  PubMed  Google Scholar 

  69. Sinclair CF, Gurey LE, Blitzer A. Oromandibular dystonia: long-term management with botulinum toxin. Laryngoscope. 2013;123:3078–83.

    Article  CAS  PubMed  Google Scholar 

  70. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999;53:2102–7.

    Article  CAS  PubMed  Google Scholar 

  71. Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc. 2000;131:211–6.

    Article  CAS  PubMed  Google Scholar 

  72. Tinastepe N, Küçük BB, Oral K. Botulinum toxin for the treatment of bruxism. Cranio. 2015;33(4):291–8.

    Article  PubMed  Google Scholar 

  73. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. Cranio. 2008;26:126–35.

    Article  PubMed  Google Scholar 

  74. Lee SJ, WD MC Jr, Kim YK, Chung SC, Chung JW. Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil. 2010;89:16–23.

    Article  PubMed  Google Scholar 

  75. Ondo WG, Simmons JH, Ondo VH, Hunter C, Jankovic J. Onabotulinum toxin-A injections for sleep bruxism: a double-blind, placebo controlled, parallel design, polysomnographic study. Neurology. 2016;78(1)

    Google Scholar 

  76. Norby E, Orbelo D, Strand E, Duffy J, Ekbom D, Bower J, et al. Hyoid muscle dystonia: a distinct focal dystonia syndrome. Parkinsonism Relat Disord. 2015;21(10):1210–3.

    Article  CAS  PubMed  Google Scholar 

  77. Hallett M, Benecke R, Blitzer A, Comella CL. Treatment of focal dystonias with botulinum neurotoxin. Toxicon. 2009;54:628–33.

    Article  CAS  PubMed  Google Scholar 

  78. Thenganatt MA, Fahn S. Botulinum toxin for the treatment of movement disorders. Curr Neurol Neurosci Rep. 2012;12:399–409.

    Article  CAS  PubMed  Google Scholar 

  79. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990;53:633–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Esper CD, Freeman A, Factor SA. Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord. 2010;16:438–41.

    Article  PubMed  Google Scholar 

  81. Nastasi L, Mostile G, et al. Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue. J Neurol. 2016;263(9):1702–8.

    Article  CAS  PubMed  Google Scholar 

  82. Sitburana O, Wu LJ, Sheffield JK, Davidson A, Jankovic J. Motor overflow and mirror dystonia. Parkinsonism Relat Disord. 2009;15(10):758–61.

    Article  PubMed  Google Scholar 

  83. Tolosa E, Compta Y. Dystonia in Parkinson’s disease. J Neurol. 2006;253(Suppl 7):VII7–13.

    PubMed  Google Scholar 

  84. Kruisdijk JJM, Koelman JHTM, de Visser BWO, de Haan RJ, Speelman JD. Botulinum toxin for writer’s cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry. 2007;78(3):264–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Contarino MF, Kruisdijk JJM, Koster L, et al. Sensory integration in writer’s cramp: comparison with controls and evaluation of botulinum toxin effect. Clin Neurophysiol. 2007;118(10):2195–206.

    Article  CAS  PubMed  Google Scholar 

  86. Tsui JK, Bhatt M, Calne S, Calne DB. Botulinum toxin in the treatment of writer’s cramp: a double-blind study. Neurology. 1993;43:183–5.

    Article  CAS  PubMed  Google Scholar 

  87. Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology. 1992;42:627–30.

    Article  CAS  PubMed  Google Scholar 

  88. Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. “Off” painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov Disord. 1995;10:333–6.

    Article  CAS  PubMed  Google Scholar 

  89. Mahapatra RK, Edwards MJ, Schott JM, Bhatia KP. Corticobasal degeneration. Lancet Neurol. 2004;3:736–43.

    Article  PubMed  Google Scholar 

  90. Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord. 2001;16:907–13.

    Article  CAS  PubMed  Google Scholar 

  91. Shehata HS, Shalaby NM, Esmail EH, Fahmy E. Corticobasal degeneration: clinical characteristics and multidisciplinary therapeutic approach in 26 patients. Neurol Sci. 2015;36:1651–7.

    Article  PubMed  Google Scholar 

  92. Armstrong MJ. Diagnosis and treatment of corticobasal degeneration. Curr Treat Options Neurol. 2014;16:282.

    Article  PubMed  Google Scholar 

  93. Defazio G, Jankovic J, Giel JL, Papapetropoulos S. Descriptive epidemiology of cervical dystonia. Tremor Other Hyperkin Mov. 2013;3

    Google Scholar 

  94. Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007;13:411–6.

    Article  CAS  PubMed  Google Scholar 

  95. Patel N, Hanfelt J, Marsh L, Jankovic J, Members of the Dystonia Coalition. Alleviating manoeuvres (sensory tricks) in cervical dystonia. J Neurol Neurosurg Psychiatry. 2014;85(8):882–4.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Jankovic J. Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Mov Disord. 2010;25(5):527–8b.

    Article  PubMed  Google Scholar 

  97. Peng-Chen Z, Thompson A, Rodriguez RL. Bilateral lower sternocleidomastoid Botulinum toxin injections to address refractory Anterocollis. Neurologist. 2016;21:30–1.

    Article  PubMed  Google Scholar 

  98. Allison SK, Odderson IR. Ultrasound and electromyography guidance for injection of the Longus Colli with Botulinum toxin for the treatment of cervical dystonia. Ultrasound Q. 2016;32(3):302–6.

    Article  PubMed  Google Scholar 

  99. Herting B, Wunderlich S, Glockler T, Bendszus M, Mucha D, Reichmann H, et al. Computed tomographically-controlled injection of botulinum toxin into the longus colli muscle in severe anterocollis. Mov Disord. 2004;19:588–90.

    Article  PubMed  Google Scholar 

  100. Finsterer J, Maeztu C, Revuelta GJ, Reichel G, Truong D. Collum-caput (COL-CAP) concept for conceptual anterocollis, anterocaput, and forward sagittal shift. J Neurol Sci. 2015;355:37–43.

    Article  PubMed  Google Scholar 

  101. Papapetropoulos S, Baez S, Zitser J, Sengun C, Singer C. Retrocollis: classification, clinical phenotype, treatment outcomes and risk factors. Eur Neurol. 2008;59:71–5.

    Article  PubMed  Google Scholar 

  102. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia. Drugs. 2016;76:759–77.

    Article  CAS  PubMed  Google Scholar 

  103. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001;2:577–88.

    Article  CAS  PubMed  Google Scholar 

  104. Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease. Pharmacol Rev. 2013;65:171–222.

    Article  CAS  PubMed  Google Scholar 

  105. Hong JY, JS O, Lee I, Sunwoo MK, Ham JH, Lee JE, et al. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology. 2014;82:1597–604.

    Article  CAS  PubMed  Google Scholar 

  106. Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog Neurobiol. 2015;132:96–168.

    Article  CAS  PubMed  Google Scholar 

  107. Espay AJ, Vaughan JE, Shukla R, Gartner M, Sahay A, Revilla FJ, et al. Botulinum toxin type A for levodopa-induced cervical dyskinesias in Parkinson’s disease: unfavorable risk-benefit ratio. Mov Disord. 2011b;26:913–4.

    Article  PubMed  Google Scholar 

  108. Mills K, Mari Z. An update and review of the treatment of myoclonus. Curr Neurol Neurosci Rep. 2015;15:512.

    Article  PubMed  CAS  Google Scholar 

  109. Baizabal-Carvallo JF, Cardoso F, Jankovic J. Myorhythmia: phenomenology, etiology, and treatment. Mov Disord. 2015;30:171–9.

    Article  PubMed  Google Scholar 

  110. Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord. 2006;21:1856–63.

    Article  PubMed  Google Scholar 

  111. Barone P, Santangelo G, Amboni M, Pellecchia MT, Vitale C. Pisa syndrome in Parkinson’s disease and parkinsonism: clinical features, pathophysiology, and treatment. Lancet Neurol. 2016;15(10):1063–74.

    Article  PubMed  Google Scholar 

  112. Bertram KL, Stirpe P, et al. Treatment of camptocormia with botulinum toxin. Toxicon. 2015;107(Pt A):148–53.

    Article  CAS  PubMed  Google Scholar 

  113. Srivanitchapoom P, Hallett M. Camptocormia in Parkinson’s disease: definition, epidemiology, pathogenesis and treatment modalities. J Neurol Neurosurg Psychiatry. 2016;87:75–85.

    PubMed  Google Scholar 

  114. Peeraully T, Tan E-K. Camptocormia in Parkinson’s disease: dystonia or myopathy? Basal Ganglia. 2012;2:1–3.

    Article  Google Scholar 

  115. Hellmann MA, Djaldetti R, Israel Z, Melamed E. Effect of deep brain subthalamic stimulation on camptocormia and postural abnormalities in idiopathic Parkinson's disease. Mov Disord. 2006;21:2008–10.

    Article  PubMed  Google Scholar 

  116. Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology. 2005;65:355–9.

    Article  PubMed  Google Scholar 

  117. Colosimo C, Salvatori FM. Injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord. 2009;24:316–7.

    Article  PubMed  Google Scholar 

  118. Adler CH, Beach TG. Neuropathological basis of nonmotor manifestations of Parkinson’s disease. Mov Disord. 2016;31(8):1114–9.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Ahsan SF, Meleca RJ, Dworkin JP. Botulinum toxin injection of the cricopharyngeus muscle for the treatment of dysphagia. Otolaryngology. 2000;122:691–5.

    CAS  Google Scholar 

  120. Albanese A, Brisinda G, Bentivoglio AR, Maria G. Treatment of outlet obstruction constipation in Parkinson’s disease with botulinum neurotoxin A. Am J Gastroenterol. 2003;98:1439–40.

    Article  CAS  PubMed  Google Scholar 

  121. Alfonsi E, Merlo IM, Ponzio M, Montomoli C, Tassorelli C, Biancardi C, et al. An electrophysiological approach to the diagnosis of neurogenic dysphagia: implications for botulinum toxin treatment. J Neurol Neurosurg Psychiatry. 2010;81:54–60.

    Article  CAS  PubMed  Google Scholar 

  122. Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, et al. Pharmacological treatment of overactive bladder: report from the international consultation on incontinence. Curr Opin Urol. 2009;19:380–94.

    Article  PubMed  Google Scholar 

  123. Annese V, Bassotti G, Coccia G, Dinelli M, D'Onofrio V, Gatto G, et al. A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group. Gut. 2000;46:597–600.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Apostolidis A, Fowler CJ. The use of botulinum neurotoxin type A (BoNTA) in urology. J Neural Transm. 2008;115:593–605.

    Article  CAS  PubMed  Google Scholar 

  125. Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson’s disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry. 2000;68:429–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Arsic Arsenijevic VS, Milobratovic D, Barac AM, Vekic B, Marinkovic J, Kostic VS. A laboratory-based study on patients with Parkinson’s disease and seborrheic dermatitis: the presence and density of Malassezia yeasts, their different species and enzymes production. BMC Dermatol. 2014;14:5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  127. Blackett H, Walker R, Wood B. Urinary dysfunction in Parkinson’s disease: a review. Parkinsonism Relat Disord. 2009;15:81–7.

    Article  PubMed  Google Scholar 

  128. Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope. 2001;111:218–26.

    Article  CAS  PubMed  Google Scholar 

  129. Borghammer P, Knudsen K, Brooks DJ. Imaging systemic dysfunction in Parkinson’s disease. Curr Neurol Neurosci Rep. 2016;16:51.

    Article  PubMed  Google Scholar 

  130. Cadeddu F, Bentivoglio AR, Brandara F, Marniga G, Brisinda G, Maria G. Outlet type constipation in Parkinson’s disease: results of botulinum toxin treatment. Aliment Pharmacol Ther. 2005;22:997–1003.

    Article  CAS  PubMed  Google Scholar 

  131. Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33:17–30.

    Article  CAS  PubMed  Google Scholar 

  132. Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson’s disease: a prospective double-blind trial. Mov Disord. 2012;27:219–26.

    Article  CAS  PubMed  Google Scholar 

  133. Chou KL, Evatt M, Hinson V, Kompoliti K. Sialorrhea in Parkinson’s disease: a review. Mov Disord. 2007;22:2306–13.

    Article  PubMed  Google Scholar 

  134. Chuang YC, Chancellor MB. The application of botulinum toxin in the prostate. J Urol. 2006;176:2375–82.

    Article  CAS  PubMed  Google Scholar 

  135. Damian A, Adler CH, Hentz JG, Shill HA, Caviness JN, Sabbagh MN, et al. Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:1089–93.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Diamond A, Jankovic J. Botulinum toxin in dermatology—beyond wrinkles and sweat. J Cosmet Dermatol. 2006;5:169.

    Article  PubMed  Google Scholar 

  137. Dogu O, Apaydin D, Sevim S, Talas DU, Aral M. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. Clin Neurol Neurosurg. 2004;106:93–6.

    Article  PubMed  Google Scholar 

  138. Ellerston JK, Heller AC, Houtz DR, Kendall KA. Quantitative measures of swallowing deficits in patients with Parkinson’s disease. Ann Otol Rhinol Laryngol. 2016;125:385–92.

    Article  PubMed  Google Scholar 

  139. Fietzek UM, Schroeteler FE, Ceballos-Baumann AO. Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin. Mov Disord. 2009;24:2027–8.

    Article  PubMed  Google Scholar 

  140. Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G, et al. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J Urol. 2011;186:960–4.

    Article  CAS  PubMed  Google Scholar 

  141. Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy. J Urol. 2009;182:1453–7.

    Article  PubMed  Google Scholar 

  142. Haapaniemi JJ, Laurikainen EA, Pulkkinen J, Marttila RJ. Botulinum toxin in the treatment of cricopharyngeal dysphagia. Dysphagia. 2001;16:171–5.

    Article  CAS  PubMed  Google Scholar 

  143. Hoogerwerf WA, Pasricha PJ. Pharmacologic therapy in treating achalasia. Gastrointest Endosc Clin N Am. 2001;11:311–24. vii

    CAS  PubMed  Google Scholar 

  144. Jankovic J. The use of botulinum toxin in tic disorders and essential hand and head tremor. In: Truong D, Dressler D, Hallett M, editors. Manual of botulinum toxin therapy. Cambridge: Cambridge University Press; 2013. p. 160–7.

    Google Scholar 

  145. Johnston BT, Colcher A, Li Q, Gideon RM, Castell JA, Castell DO. Repetitive proximal esophageal contractions: a new manometric finding and a possible further link between Parkinson’s disease and achalasia. Dysphagia. 2001;16:186–9.

    Article  CAS  PubMed  Google Scholar 

  146. Kulaksizoglu H, Parman Y. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons’s disease. Parkinsonism Relat Disord. 2010;16:531–4.

    Article  PubMed  Google Scholar 

  147. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2006;21:704–7.

    Article  PubMed  Google Scholar 

  148. Lakraj AA, Moghimi N, Jabbari B. Sialorrhea: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins (Basel). 2013;5:1010–31.

    Article  CAS  Google Scholar 

  149. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003;61:1279–81.

    Article  CAS  PubMed  Google Scholar 

  150. Lynch AC, Frizelle FA. Colorectal motility and defecation after spinal cord injury in humans. Prog Brain Res. 2006;152:335–43.

    Article  CAS  PubMed  Google Scholar 

  151. Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord. 2003;18:685–8.

    Article  PubMed  Google Scholar 

  152. Martignoni E, Godi L, Pacchetti C, Berardesca E, Vignoli GP, Albani G, et al. Is seborrhea a sign of autonomic impairment in Parkinson’s disease? J Neural Transm. 1997;104:1295–304.

    Article  CAS  PubMed  Google Scholar 

  153. Moonen AJ, Boeckxstaens GE. Management of achalasia. Gastroenterol Clin N Am. 2013;42:45–55.

    Article  Google Scholar 

  154. Mostile G, Jankovic J. Treatment of dysautonomia associated with Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(Suppl 3):S224–32.

    Article  PubMed  Google Scholar 

  155. Murray CA, Cohen JL, Solish N. Treatment of focal hyperhidrosis. J Cutan Med Surg. 2007;11:67–77.

    Article  CAS  PubMed  Google Scholar 

  156. Naumann M, Jost W. Botulinum toxin treatment of secretory disorders. Mov Disord. 2004;19(Suppl 8):S137–41.

    Article  PubMed  Google Scholar 

  157. Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1707–14.

    Article  CAS  PubMed  Google Scholar 

  158. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology. 2004;62:37–40.

    Article  CAS  PubMed  Google Scholar 

  159. Pasricha PJ, Rai R, Ravich WJ, Hendrix TR, Kalloo AN. Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology. 1996;110:1410–5.

    Article  CAS  PubMed  Google Scholar 

  160. Patel AK, Patterson JM, Chapple CR. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur Urol. 2006;50:684–709. discussion 709-610

    Article  CAS  PubMed  Google Scholar 

  161. Pfeiffer RF. Neurologic presentations of gastrointestinal disease. Neurol Clin. 2010;28:75–87.

    Article  PubMed  Google Scholar 

  162. Pinnington LL, Muhiddin KA, Ellis RE, Playford ED (2000) Non-invasive assessment of swallowing and respiration in Parkinson’s disease. J Neurol 247:773–777.

    Google Scholar 

  163. Proulx M, de Courval FP, Wiseman MA, Panisset M. Salivary production in Parkinson’s disease. Mov Disord. 2005;20:204–7.

    Article  PubMed  Google Scholar 

  164. Richter JE, Boeckxstaens GE. Management of achalasia: surgery or pneumatic dilation. Gut. 2011;60:869–76.

    Article  PubMed  Google Scholar 

  165. Rodriguez-Blazquez C, Forjaz MJ, Frades-Payo B, de Pedro-Cuesta J, Martinez-Martin P, Longitudinal Parkinson’s Disease Patient Study ELdPcEdPG. Independent validation of the scales for outcomes in Parkinson’s disease-autonomic (SCOPA-AUT). Eur J Neurol. 2010;17:194–201.

    Article  CAS  PubMed  Google Scholar 

  166. Rossi M, Merello M, et al. Management of constipation in Parkinson’s disease. Expert Opin Pharmacother. 2015;16(4):547–57.

    Article  CAS  PubMed  Google Scholar 

  167. Sakakibara R, Tateno F, Nagao T, Yamamoto T, Uchiyama T, Yamanishi T, et al. Bladder function of patients with Parkinson’s disease. Int J Urol. 2014;21:638–46.

    Article  CAS  PubMed  Google Scholar 

  168. Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H, The Parkinson's Disease Subcomittee, The Neurourology Promotion Committee in The International Continence Society. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn. 2016;35:551–63.

    Article  PubMed  Google Scholar 

  169. Schestatsky P, Valls-Sole J, Ehlers JA, Rieder CR, Gomes I. Hyperhidrosis in Parkinson’s disease. Mov Disord. 2006;21:1744–8.

    Article  PubMed  Google Scholar 

  170. Schneider I, Thumfart WF, Pototschnig C, Eckel HE. Treatment of dysfunction of the cricopharyngeal muscle with botulinum A toxin: introduction of a new, noninvasive method. Ann Otol Rhinol Laryngol. 1994;103:31–5.

    Article  CAS  PubMed  Google Scholar 

  171. Sheffield JK, Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev Neurother. 2007;7:637–47.

    Article  CAS  PubMed  Google Scholar 

  172. Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33:908–23.

    CAS  PubMed  Google Scholar 

  173. Srivanitchapoom P, Pandey S, Hallett M. Drooling in Parkinson’s disease: a review. Parkinsonism Relat Disord. 2014;20(11):1109–18.

    Article  PubMed  PubMed Central  Google Scholar 

  174. Swinn L, Schrag A, Viswanathan R, Bloem BR, Lees A, Quinn N. Sweating dysfunction in Parkinson’s disease. Mov Disord. 2003;18:1459–63.

    Article  PubMed  Google Scholar 

  175. Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005;65:765–7.

    Article  CAS  PubMed  Google Scholar 

  176. Tison F, Yekhlef F, Chrysostome V, Sourgen C. Prevalence of multiple system atrophy. Lancet. 2000;355:495–6.

    Article  CAS  PubMed  Google Scholar 

  177. Tumilasci OR, Cersosimo MG, Belforte JE, Micheli FE, Benarroch EE, Pazo JH. Quantitative study of salivary secretion in Parkinson’s disease. Mov Disord. 2006;21:660–7.

    Article  PubMed  Google Scholar 

  178. Vanek ZF, Jankovic J. Dystonia in corticobasal degeneration. Adv Neurol. 2000;82:61–7.

    CAS  PubMed  Google Scholar 

  179. von Coelln R, Raible A, Gasser T, Asmus F. Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord. 2008;23:889–92.

    Article  Google Scholar 

  180. Wang CP, Sung WH, Wang CC, Tsai PY. Early recognition of pelvic floor dyssynergia and colorectal assessment in Parkinson’s disease associated with bowel dysfunction. Colorectal Dis. 2013;15:e130–7.

    Article  PubMed  Google Scholar 

  181. Winge K, Fowler CJ. Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord. 2006;21:737–45.

    Article  PubMed  Google Scholar 

  182. van de Warrenburg BP, Cordivari C, Ryan AM, Phadke R, Holton JL, Bhatia KP, Hanna MG, Quinn NP. The phenomenon of disproportionate antecollis in Parkinson’s disease and multiple system atrophy. Mov Disord. 2007;22(16):2325–31.

    Article  PubMed  Google Scholar 

  183. Tarakad A, Jankovic J. Diagnosis and management of Parkinson’s disease. Semin Neurol. 2017;37(2):118–26.

    Article  PubMed  Google Scholar 

  184. Wollina U, Konrad H, Petersen S. Botulinum toxin in dermatology—beyond wrinkles and sweat. J Cosmet Dermatol. 2005;4(4):223–7.

    Article  PubMed  Google Scholar 

  185. Mathers SE, Kempster PA, Law PJ, Frankel JP, Bartram CI, Lees AJ, Stern GM, Swash M. Anal sphincter dysfunction in Parkinson’s disease. Arch Neurol. 1989;46(10):1061–4.

    Article  CAS  PubMed  Google Scholar 

  186. de Groat WC, Nadelhaft I, Milne RJ, Booth AM, Morgan C, Thor K. Organization of the sacral parasympathetic reflex pathways to the urinary bladder and large intestine. J Auton Nerv Syst. 1981;3(2-4):135–60.

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

Dr. Jankovic has received research and/or training grants from Allergan, Inc.; Dystonia Medical Research Foundation; Merz Pharmaceuticals; Revance Therapeutics, Inc.

Dr. Jankovic has served as a consultant or as an advisory committee member for: Allergan, Inc.; Revance Therapeutics, Inc.

Author information

Authors and Affiliations

  1. Department of Neurology, Parkinson’s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 7200 Cambridge, Suite 9A, Houston, TX, 77030-4202, USA

    Parul Jindal M.D. & Joseph Jankovic M.D.

Authors
  1. Parul Jindal M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph Jankovic M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Parul Jindal M.D. .

Editor information

Editors and Affiliations

  1. Emeritus Professor of Neurology, Yale University, New Haven, Connecticut, USA

    Bahman Jabbari

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Jindal, P., Jankovic, J. (2018). Botulinum Toxin Treatment in Parkinson’s Disease and Atypical Parkinsonian Disorders. In: Jabbari, B. (eds) Botulinum Toxin Treatment in Clinical Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-56038-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56038-0_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56037-3

  • Online ISBN: 978-3-319-56038-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation